Eli Lilly reported a 48% revenue increase to $23 billion in Q2 2026, driven mainly by strong sales of Mounjaro and Zepbound. Earnings per share rose 26% to $7.94 on a reported basis, with non-GAAP EPS up 33% to $8.38. The company raised its full-year 2026 revenue guidance to $85-$87 billion and updated EPS guidance to $35.50-$36.50, despite higher acquired IPR&D charges. Regulatory approvals and positive clinical trial results, especially for obesity drug retatrutide, support future growth prospects.
US stock indexes are poised to reach new record highs as oil prices stabilize after a recent sharp decline, easing inflation concerns and boosting risk appetite. Dow Jones and S&P 500 futures rose 0.4%, while Nasdaq futures gained 0.2%, despite signi...
Eli Lilly reported second-quarter earnings and revenue that exceeded expectations, driven by strong sales of its weight loss drug Zepbound and diabetes treatment Mounjaro. The company raised its 2026 revenue forecast to $85-$87 billion from $82-$85 b...
CVS Health exceeded second-quarter earnings and revenue expectations, driven by strong performance in its insurance, pharmacy, and health services segments. The company raised its 2026 profit guidance to $7.90-$8.10 per share and revenue outlook to a...
CVS Health has revamped its weight management program to improve access to FDA-approved GLP-1 medications, including Zepbound, Foundayo, and Wegovy, through both insurance and cash-pay options. The program features a $29 online MinuteClinic visit wit...
Amplia Therapeutics has entered a clinical collaboration with Eli Lilly to test their drug narmafotinib combined with Lilly's KRAS G12C inhibitor olomorasib in advanced non-small cell lung cancer (NSCLC) patients. The Phase 1b/2b trial will evaluate ...
